Home
About
News
Events
Shop
Directory
Contact Us

Search

Sign in

Welcome! Log into your account

your username

your password

Forgot your password? Get help

Password recovery

Recover your password

your email

A password will be e-mailed to you.

Home
About
News
Events
Shop
Directory
Contact Us

The Psychedelic News Feed: Dec 11 2023 – Jan 7, 2024

By

-

January 22, 2024

15

Previous articlePsychedelics M&A and Partnerships in 2023

Next articlePT480 – Psychedelics and Consent: Power Dynamics, Boundaries, and the Concept of ‘Safe Enough’

https://psynews.com

RELATED ARTICLES MORE FROM AUTHOR

Pα+ Psychedelic Bulletin #207: Lykos Rebrands to Resilient; Pharma Pushes Back on Norway’s Ketamine Reimbursement Decision; AbbVie-Gilgamesh Deal Viewed as Validation

Matt Xavier -The Psychedelic DJ

AbbVie to Acquire Gilgamesh’s Bretisilocin for Up to $1.2B

Newsletter

EDITOR PICKS

Pα+ Psychedelic Bulletin #207: Lykos Rebrands to Resilient; Pharma Pushes Back...

Matt Xavier -The Psychedelic DJ

AbbVie to Acquire Gilgamesh’s Bretisilocin for Up to $1.2B

POPULAR POSTS

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

POPULAR CATEGORY

ABOUT US

PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.

FOLLOW US

©